 |
|
|---|---|
 |
|
| valganciclovir |
A five-year agreement between Roche and Unitaid’s Medicines Patent Pool (MPP) will make more antiviral drugs available at knock-down prices in developing countries.
Roche has agreed to supply Valcyte (valganciclovir) at a discount of up to 90% in 138 designated countries, to treat patients with cytomegalovirus as a complication of HIV. The agreement also allows for third parties to license Roche’s valganciclovir patent and develop generic versions of the drug after one year of exclusive sales.
Firm will supply cheap drugs and allow generics in developing countries
Valganciclovir hydrochloride (Valcyte, manufactured by Hoffmann–La Roche (Roche), and also known as Cymeval, Valcyt, Valixa, Darilin, Rovalcyte, Patheon, and Syntex) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
credit-chemdrug
